Abstracts

113 – Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV

Background In a recent pilot study (ACTG A5371, SLIM LIVER: NCT04216589), 24 weeks of low-dose semaglutide (1 mg sc weekly) reduced metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV (PWH), with 58% having improved MRI-proton-derived fat fraction-quantified intrahepatic triglycerides (IHTG). Although trends suggested greater IHTG improvements in women and older participants, the role…

178 – Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy

Background REPRIEVE established that pitavastatin prevents major adverse cardiovascular events (MACE) and reduces noncalcified coronary plaque (NCP) on coronary CT angiography, in low-moderate risk PWH. We leveraged the REPRIEVE Mechanistic Substudy to assess for the first time the relationship of coronary plaque and indices of inflammation and subclinical myocardial injury with MACE and the effects…

175 – Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study

Background Antiretroviral therapy (ART) has transformed HIV from a life-threatening infection into a manageable chronic condition, allowing people living with HIV (PLWH) to have a significantly longer lifespan. However, as this population ages, they become increasingly susceptible to non-AIDS-related comorbidities typically associated with aging. Understanding the evolving patterns of these age-related conditions is essential to…

128 – All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania

Background Comparing cause-specific mortality among people with HIV (PWH) and people without HIV (PWOH) is important for tracking improved survival following increased antiretroviral therapy (ART) access. However, comprehensive data on cause-specific mortality rates in Sub-Saharan Africa remains inadequate. We estimated mortality trends in Tanzania.  Methods Data were collected in a health and demographic surveillance system…

180 – Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection

Background Epigenetic age acceleration has prognostic value in the general population. However, its role in predicting clinical outcomes in people with HIV (PWH) with long-term virological suppression remains unclear Methods Retrospective cohort of PWH with long-term virological suppression, followed at a single HIV unit. Blood DNA methylation was assessed using the Illumina Infinium MethylationEPIC BeadChip,…

122 – Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study

Background Dolutegravir (DTG) is not recommended for neonates due to absence of dosing guidelines and safety information. We are evaluating the multi-dose pharmacokinetics (PK) and safety of two pediatric DTG formulations in neonates: a dispersible scored tablet (DTG-DT, 10 mg) and a novel oral dispersible film (DTG-OF, 5 mg). Methods PETITE-DTG is an ongoing phase…